Abbott Laboratories (ABT)vsDexCom Inc (DXCM)
ABT
Abbott Laboratories
$84.32
-3.09%
HEALTHCARE · Cap: $151.56B
DXCM
DexCom Inc
$60.61
-0.49%
HEALTHCARE · Cap: $23.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 837% more annual revenue ($45.13B vs $4.82B). DXCM leads profitability with a 19.3% profit margin vs 13.9%. DXCM appears more attractively valued with a PEG of 1.12. DXCM earns a higher WallStSmart Score of 72/100 (B).
ABT
Buy56
out of 100
Grade: C
DXCM
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+0.6%
Fair Value
$87.53
Current Price
$84.32
$3.21 discount
Margin of Safety
+90.0%
Fair Value
$679.65
Current Price
$60.61
$619.04 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Every $100 of equity generates 36 in profit
Earnings expanding 92.2% YoY
Strong operational efficiency at 21.4%
15.0% revenue growth
Areas to Watch
Weak financial health signals
Earnings declined 19.7%
Moderate valuation
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are Piotroski F-Score, EPS Growth.
Bear Case : DXCM
The primary concerns for DXCM are P/E Ratio.
Key Dynamics to Monitor
ABT profiles as a value stock while DXCM is a mature play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.40 — expect wider price swings.
DXCM is growing revenue faster at 15.0% — sustainability is the question.
ABT generates stronger free cash flow (916M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 56/100), backed by strong 19.3% margins and 15.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?